NFL star quarterback Aaron Rodgers will be a featured speaker at a psychedelics conference to be held in Denver this summer, less than a year after Colorado voters decriminalized the therapeutic use of psilocybin mushrooms. Touted by the Multidisciplinary Association for Psychedelic Studies (MAPS) as the “largest psychedelic gathering in history,” the Psychedelic Science 2023 conference will take place in June at the Colorado Convention Center.

Last year, the Green Bay Packers star quarterback revealed that he had traveled to South America to try the psychedelic ayahuasca on more than one occasion. Rodgers said that the experience changed his mindset and had a positive effect on his mental health, crediting the drug with helping him subsequently be selected as the NFL’s most valuable player two seasons in a row. In December, he added that using ayahuasca and psilocybin mushrooms has helped him cope with a strong fear of death he has had since he was a teenager.

Rodgers has been very open about his use of psychedelics and has said he hopes that sharing his experience can help dispel the stigma attached to the powerful compounds. And in June, he will be one of more than 300 speakers to address the Psychedelic Science 2023 conference in Denver. Presented by MAPS, the gathering has been hailed by the psychedelics research and advocacy nonprofit organization as the “definitive event of the psychedelic renaissance.”

“Aaron Rodgers will be interviewed by Aubrey Marcus at Psychedelic Science 2023 about his experiences with Ayahuasca, which he’s previously spoken about on Aubrey’s podcast,” said MAPS founder and executive director Rick Doblin. “We’re delighted Aaron is open to sharing his views at what will become the world’s largest psychedelic conference ever.” 

Psychedelic drugs including LSD, psilocybin, and ayahuasca have received renewed interest from researchers for their potential to treat a wide range of mental health conditions including depression, anxiety, post-traumatic stress disorder, and substance misuse disorders. In November, Colorado voters took new steps in psychedelic policy reform with the passage of Proposition 122, a ballot measure to legalize the possession and therapeutic use of certain natural psychedelic drugs including psilocybin mushrooms, DMT, ibogaine and mescaline, for people age 21 and older. The measure also authorizes the establishment of “healing centers” where adults can obtain access to natural psychedelics for therapeutic purposes. The measure, which passed with more than 53% of the vote, is now in the process of being implemented by state officials.

Aaron Rodgers And Psychedelics

Last weekend during an appearance on the The Pat McAfee Show, Rodgers said that he would make a decision about retiring from professional football after he takes a four-day “darkness retreat” later this month. The 18-year NFL veteran said that the retreat will include “‘sensory deprivation isolation’ that will simulate the drug DMT with the potential for hallucinations,” according to a report from CBS Sports. 

“It’s an opportunity to do a little self-reflection in some isolation and after that, I feel like I’ll be a lot closer to that final, final decision,” Rodgers said on Tuesday. “I’ve had a number of friends who’ve done it and they had profound experiences.” 

In August, Rodgers revealed that he had traveled to South America to take ayahuasca before being selected as the league’s most valuable player in back-to-back seasons, saying the traditional psychedelic brew changed his thinking and significantly improved his mental health. Rodgers made the revelations about ayahuasca experiences during an appearance on the Aubrey Marcus Podcast, saying that the psychedelic drug helped him find self-love and mental wellness.

The Super Bowl champion quarterback said he made the trip to South America before winning the MVP award for the third and fourth time. Following the ayahuasca experience, he said, he “knew that [he] was never going to be the same.”

“For me, I didn’t do that and think ‘oh, I’m never playing football again,’” Rodgers said, as quoted by USA Today. “No, it gave me a deep and meaningful appreciation for life. My intention the first night going in was ‘I want to feel what pure love feels like.’ That was my intention. And I did. I really did. I had a magical experience with the sensation of feeling a hundred different hands on my body imparting a blessing of love and forgiveness for myself and gratitude for this life from what seemed to be my ancestors.”

The Psychedelic Science 2023 conference takes place at the Colorado Convention Center from June 19 through June 23. Other featured speakers include Doblin, groundbreaking researcher Robin Carhart-Harris, wellness guru Deepak Chopra, and Amanda Feilding, the executive director at the U.K.-based psychedelics advocacy organization the Beckley Foundation.

The post Aaron Rodgers To Speak at Denver Psychedelics Conference appeared first on High Times.

Sen. Ron Kouchi introduced Senate Bill 1454 on Jan. 25, which was unanimously passed in the Hawaii Senate Committee on Health and Human Services (HHS) on Feb. 6. If the bill becomes law, it would establish a “therapeutic psilocybin working group” (managed by the Office of Wellness & Resilience [OWR]) to “Examine the medicinal and therapeutic effects of psilocybin or psilocybin-based products vis-à-vis mental health including post-traumatic stress disorder, depression, anxiety, and end-of-life psychological distress.”

The group would also be tasked with evaluating how markets such as regulators in Oregon and Colorado are tackling their own state psilocybin programs, with the goal of developing a comprehensive approach for Hawaii. In effect, the place would ensure that psilocybin access is safe, accessible, and affordable for patients.

During the hearing on Feb. 6, numerous testimonies were presented in favor of passing the bill to allow psilocybin access. The HHS compiled these testimonies on a 117-page document, which included a variety of speakers, beginning with a statement from Tia Roberts Hartsock, Executive Director of the OWR with the Office of the Governor. “As negative impacts of the COVID-19 pandemic continue to show up in our daily lives, promising interventions for mental health disorders should be included in conversations relating to trauma,” Hartsock wrote. “To make informed decisions on how we should address and resource attention on complex social issues like mental health disorders, research needs to be examined. The OWR supports the purpose of SB1454 to establish a working group to provide recommendations on their findings on the potential benefits of the therapeutic use of psilocybin.”

The Drug Policy Forum of Hawaii Board President, Nikos Leverenz, also expressed support for the bill. “Hawai῾i should endeavor to work more proactively in creating a climate that is conducive to allowing qualified medical professionals to use psilocybin as a therapeutic tool for those who could benefit from its supervised use,” Leverenz said.

Patients who had personal experiences with plant medicine treatments also shared how the bill could help countless others. “l can attest without hesitation that plant medicines are both safe and effective means by which to address and recover from intense psychological and physical trauma,” said Wyly Gray, Executive Director of Veterans of War. “Veterans of War sees firsthand the healing potential of these ancient medicines day in and day out, and we advocate strongly for their decriminalization on behalf of a nation of veterans suffering from the after-effects of war, as a group, we deserve a safe and effective path towards recovery; as a group, we simply want to come home. This is bigger than the failed War on Drugs; lives are lost every day.”

This year has been productive for Hawaii legislators looking into plant medicine and legalization. On Jan. 11, Rep. Jeanné Kapela spoke about introducing an adult-use cannabis bill. “We all know, and Hawaii’s people know, that it is high time to legalize recreational cannabis use for adults in Hawaii. This year we stand on the precipice of history,” Kapela stated. “Following the recommendations of a task force devoted to addressing cannabis policy, we now have a roadmap for legalizing recreational cannabis in our islands.” Kapela has not yet introduced her bill, but she explained that it would include a mass expungement program. “Social equity. People. That is what forms the heart of our proposal,” she explained.

The people of Hawaii also recently showed support for cannabis legalization through a poll conducted by the Hawaii Cannabis Industry Association. The survey revealed that 52% of Hawaii residents are in favor of legalization (with 31% saying they are opposed).

The post Hawaii Senate Hearing Garners Overwhelming Support for Psilocybin Bill appeared first on High Times.

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) was asked by the OTC Markets group to issue an explanation behind the timing of Feb. 6 promotional emails and its stock price doubling at one point Thursday.

The OTC further requested that the company to clarify whether it has participated in what is commonly known as a “pump-and-dump” scheme, where false or misleading information is proliferated to create a buying fever that would “pump” up the price of a stock before moving to “dump” stock shares via selling their own shares at an inflated price.

“The company has not,” Awakn wrote in a Feb. 9 statement.

According to Awakn, an inquiry by management proved that “none of the company’s executive officers, directors or, to the knowledge of the company, any controlling shareholders or third party service providers, sold or purchased shares of common stock of the company within the past 90 days.”

Awakn said that it has simply continued work under an investor communications and digital marketing agreement with JRZ Capital LLC, which was disclosed in an Oct. 8, 2021, press release. JRZ Capital LLC was paid $50,000 in January this year to help send promotional emails for Awakn until the end of March.

On Monday, “OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and its common stock traded on the OTCQB Marketplace, specifically the distribution of promotional emails by third-parties, SmallCapFirm, StockWireNews, and Stock Street Wire discussing the float as well as potential catalysts of the company and summaries of recent press releases,” Awakn wrote in a Feb. 9 statement.

“The company was not involved in the creation of the materials, however has subsequently reviewed the specific details related to the company, and has confirmed these to be factual,” the company continued.

Awakn said that it is aware that the promotional activity “coincided with increased trading activity in the company’s common shares beginning on Feb. 6, 2023.”

However, the company said it didn’t believe the promotional activities were the only reason for the hike in trade volume this week, but rather attributed the increase to “currently heightened investor interest as a result of its recent press releases which disclosed that it had received ILAP approval in the U.K. as well as the initiation of an investigative study of a novel formulation of (S)-ketamine.”

Over the past year, Awakn has been contracting JRZ Capital, Geelon & Co, Just Capital Consulting, KCSA Strategic Communications, and Street Smart to aid in public relations and marketing efforts.

The post OTC Flags Awakn Life Sciences for Stock Promotion appeared first on Green Market Report.

Legislation proposed in Arizona would provide millions of dollars in grant funding to expand research into psilocybin––the primary psychoactive component in magic mushrooms––as a potential treatment for certain mental health conditions.

The bill, introduced by a Republican lawmaker and backed by Democrats, “would put $30 million in grants over three years toward clinical trials using whole-mushroom psilocybin to treat mental health conditions like depression and PTSD,” the Arizona Mirror reports. 

The outlet reports that one of the bill’s biggest backers is Dr. Sue Sisely, an internal medicine physician who believes that psilocybin treatment could be a boon for ailing military veterans. 

“It’s curbed their suicidality, it’s put their PTSD into remission, it’s even mitigated their pain syndromes,” Sisely said of patients she has seen benefit from psilocybin, as quoted by the Arizona Mirror. “It’s shown evidence of promoting neurogenesis (the growth and development of nerve tissue). There’s all kinds of great things that are being uncovered, but they’re not in controlled trials—they’re anecdotes from veterans and other trauma sufferers.” 

According to the Mirror, “so far the only controlled trials on psilocybin to treat medical conditions have used a synthetic, one-molecule version of the substance, which is vastly different from a whole mushroom, which contains hundreds of compounds.”

“These agricultural products are very complex, and that is what people are reporting benefit from,” Sisley told the Arizona Mirror. “Nobody in the world has access to synthetic psilocybin unless you’re in one of these big pharma trials.” 

In the last decade, psilocybin has gone from the fringes to the mainstream, as researchers and policymakers have grown more amenable to mushrooms as an effective treatment for a variety of different disorders. 

It has also become the next frontier for drug legalization advocates, as states like Arizona consider measures that would expand its usage. 

To the north of the Grand Canyon State, advocates in Utah have launched a campaign to push legislators to legalize psilocybin for clinical and academic purposes.

“Numerous robust studies have shown that psilocybin therapy is beneficial in reducing treatment-resistant depression, anxiety, addiction, trauma, obsessive-compulsive disorder, and other mental health disorders. It is more effective than synthetic pharmaceuticals by a large margin. Psilocybin has also shown effectiveness in easing fear and anxiety in people with terminal cancer. For instance, a groundbreaking study performed by John Hopkins Medicine found that psilocybin reported better moods and greater mental health after participating in a single clinical dose,” Utah Mushroom Therapy, the group behind the campaign, says in a statement.

The group is looking to gin up public support for the treatment after the state’s Republican governor, Spencer Cox, signed a bill last year establishing a task force that will study psilocybin as a mental health treatment.

Utah Mushroom Therapy says that, in the wake of the task force, “legalizing and decriminalizing Psilocybin in Utah is now very likely but still needs public support.”

“The use of mushrooms has been documented in 15 indigenous groups in America and various religious communities in Utah. This petition supports those groups who wish to use psilocybin safely, sincerely, and as a necessary part of their religion. The use of psilocybin does not contradict other Utah cultures and is protected by the first amendment as well as the Religious Freedom Restoration Act. This petition is to advocate Utah law to protect the religious rights of Utahns,” the group says. 

“Psilocybin is a natural, non-toxic substance. Despite this, it is currently a Schedule I substance. Scientists have demonstrated it has profound medicinal value and believe serotonergic hallucinogens assist cognitive processes and should be decriminalized. Psychedelics can change perception and mood, help people soften their perspective and outlook, and process events that may otherwise lead to substance abuse, trauma, and criminal behavior,” it continues.

The post Arizona Bill Would Provide Grants for Magic Mushroom Trials appeared first on High Times.